Literature DB >> 10562747

Factors influencing compliance in long-term proton pump inhibitor therapy in general practice.

A P Hungin1, G Rubin, H O'Flanagan.   

Abstract

Long-term proton pump inhibitor (PPI) prescribing in general practice is common, but only a minority of patients request their prescriptions regularly. This study determined factors linked with compliance using questionnaires and diary cards. The chief factors determining whether or not patients took their PPIs were the presence or severity of symptoms and the desire to remain in personal control, together with a fear of side-effects and lack of knowledge about the drugs. As most such prescribing is for uncomplicated gastro-oesophageal reflux disease, on-demand therapy should now be formally advocated.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10562747      PMCID: PMC1313445     

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  3 in total

1.  A qualitative study of medication-taking behaviour in primary care.

Authors:  J Dowell; H Hudson
Journal:  Fam Pract       Date:  1997-10       Impact factor: 2.267

2.  Long-term prescribing of proton pump inhibitors in general practice.

Authors:  A P Hungin; G P Rubin; H O'Flanagan
Journal:  Br J Gen Pract       Date:  1999-06       Impact factor: 5.386

Review 3.  Long-term management of gastroesophageal reflux disease.

Authors:  R C Heading
Journal:  Scand J Gastroenterol Suppl       Date:  1995
  3 in total
  27 in total

1.  Treatment of Refractory Gastroesophageal Reflux Disease.

Authors:  Rishi D Naik; Matthew H Meyers; Michael F Vaezi
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-04

Review 2.  Assessment of reflux symptom severity: methodological options and their attributes.

Authors:  P Bytzer
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

3.  Optimal Omeprazole Dosing and Symptom Control: A Randomized Controlled Trial (OSCAR Trial).

Authors:  Abhijeet Waghray; Nisheet Waghray; Adam T Perzynski; Mark Votruba; M Michael Wolfe
Journal:  Dig Dis Sci       Date:  2018-08-09       Impact factor: 3.199

4.  Effects of pantoprazole 20 mg in mildgastroesophageal reflux disease: Once-daily treatment in the acute phase, and comparison of on-demand versus continuous treatment in the long term.

Authors:  Werner Janssen; Eberhard Meier; Gudrun Gatz; Bernd Pfaffenberger
Journal:  Curr Ther Res Clin Exp       Date:  2005-07

Review 5.  Proton pump inhibitor resistance, the real challenge in gastro-esophageal reflux disease.

Authors:  Michele Cicala; Sara Emerenziani; Michele Pier Luca Guarino; Mentore Ribolsi
Journal:  World J Gastroenterol       Date:  2013-10-21       Impact factor: 5.742

Review 6.  Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know.

Authors:  Malcolm Robinson; John Horn
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 7.  On-demand and intermittent therapy for gastro-oesophageal reflux disease: economic considerations.

Authors:  John M Inadomi
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

8.  Acceptability of lansoprazole orally disintegrating tablets in patients with gastro-oesophageal reflux disease : ACEPTO study.

Authors:  Carlos Martín de Argila; Julio Ponce; Emilio Márquez; M José Plazas; Jordi Galván; Joan Heras; Joana Porcel
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

9.  The effect of gastroesophageal flap valve appearance on the management of patients with symptoms of gastroesophageal reflux disease.

Authors:  Elias Xirouchakis; Dimitrios Kamberoglou; Dimitrios Kalos; Evanthia Zambeli; Vassilios Doulgeroglou; Vassilios Tzias
Journal:  Dig Dis Sci       Date:  2008-07-04       Impact factor: 3.199

10.  Alternative vs. conventional treatment given on-demand for gastroesophageal reflux disease: a randomised controlled trial.

Authors:  Per G Farup; Mathis Heibert; Victor Høeg
Journal:  BMC Complement Altern Med       Date:  2009-02-24       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.